• Celebrex
• Alternative
• Attorney
• Black Box
• Bleeding
• Cancer
• Cardiac Problems
• Claim
• Class Action
• Danger
• Dosage
• Heart
• Heart Disease
• Information
• Label Change
• Lawsuit
• Legal
• Litigation
• Problem
• Reaction
• Safety
• Side Effects
• Stroke
• Warning
• Withdrawal
• Contact a Lawyer

Find a Lawyer in Your State

Need Help?

• Accutane®
• Cerebral Palsy
• Darvocet®
• Denture Cream
• Depuy ASR™ Hip Implant
• Fosamax® Femur Fracture
• MiniMed Insulin Pump
• Multaq®
• Nephrogenic Systemic Fibrosis
• Paxil® Birth Defects
• Propecia®
• Shoulder Pain Pump
• Topamax®
• Truck Accident Lawyer
• Wellbutrin®
• Yaz® Birth Control

On December 17, 2004, Celebrex''s maker, Pfizer, issued warning statements about the potential side effects associated with higher Celebrex dosage use. The National Cancer Institute was conducting a colorectal cancer prevention study in 100 different medical centers nationwide to test the effects of Celebrex dosage in preventing this, and other, cancers. The study was stopped short after patients taking higher Celebrex dosage reported a significantly higher rate of heart attack and stroke complications as a result of taking this medication.

Preliminary clinical trial evidence indicates that study participants who had been taking a 400 milligram Celebrex dosage were 2.5 times more likely to suffer an adverse cardiovascular event than participants in the control group. Trial patients who had been taking an 800 milligram Celebrex dosage were found to be 3.4 times more likely to suffer heart attack or stroke as a result of Celebrex use.

Celebrex is a blockbuster pain medication that has been widely prescribed since 1999 to treat patients with arthritis, severe menstrual cramps and other chronic pain conditions. The recommended Celebrex dosage for patients with osteoarthritis and primary dysmenorrhea is 100 to 200 milligrams of Celebrex as directed. The recommended Celebrex dosage for patients suffering from rheumatoid arthritis has been slightly higher at 200 to 400 milligrams of Celebrex as directed.

Though the clinical trial participants had suffered increased cardiovascular risks at a higher Celebrex dosage, it is still unclear if other Celebrex dosage carries the same cardiovascular risks. Following the announcement about potential Celebrex dosage risks, Pfizer stated that they planned to take immediate steps to evaluate the clinical trial findings in order to better understand the nature and extent of the Celebrex dosage risks. Pfizer has made no plans to issue a recall of Celebrex. However, as suggested by the FDA, all direct marketing advertisements for Celebrex have been temporarily pulled from television and other mass communication systems until the cardiovascular safety of all Celebrex dosage strengths is better understood.

Less than two weeks after news of Celebrex dosage dangers went public, new prescription sales of Celebrex have dropped fifty-six percent in the United States alone. The FDA has advised physicians and patients to consider alternatives to Celebrex dosage treatments until the cardiovascular risks have been fully assessed. An alternative to Celebrex dosage, called Mobic, has witnessed an increase in new patients with more than 24,000 prescriptions sold in December 2004 alone. Of these new patients, more than 13,000 had previously taken Celebrex dosage to treat their pain conditions.

If you are concerned about your Celebrex dosage, it is imperative to speak to your doctor before making any changes to your treatment. Your physician will be able to discuss the risks and benefits of your current Celebrex dosage and offer alternatives that are most appropriate for you.

"Celebrex safety concerns reaps benefits for alternative painkillers"

After COX-2 painkillers – Vioxx, Celebrex and Bextra- came under scrutiny when cardiovascular risks were associated to the drugs some drugmakers saw this as an opportunity to try to capitalize on the events.

Vioxx went off the market in Se...

» Read More

"Is pharmaceutical advertising too aggressive?"

Merck & Co. and Pfizer Inc. have been criticized for their aggressive marketing campaigns for its COX-2 drugs, putting scrutiny on pharmaceutical advertising as a whole. Between December 2003 and November 2004, pharmaceutical ad spending increased 30...

» Read More

"COX-2 safety questions far from answered"

A three-day FDA Advisory Committee meeting has wrapped, but the COX-2 drugs controversy is still not resolved. Although the panel of government medical experts advised keeping the drugs, including Pfizer Inc.’s Celebrex and Bextra, on the market, new...

» Read More

• Accutane® |
• Acetaminophen |
• Actavis Information |
• Actos® |
• Amiodarone |
• Trasylol® - Aprotinin Injection |
• Avandia® |
• Baycol® |
• Bextra® |
• Botox |
• Byetta® |
• Celebrex |
• Cellcept |
• Chantix® |
• Cipro Side Effects |
• Crestor |
• Darvocet |
• Darvon® |
• Defective Drug FAQ |
• Common Defective Drugs |
• Depakote® |
• Drug Company Information |
• Defective Drug Side Effects |
• Duragesic Patch |
• Exjade |
• Fentanyl |
• Fen Phen |
• Fleet Phospho Soda |
• Fluoroquinolone Antibiotics |
• Fosamax |
• Gadolinium |
• Gardasil |
• Gleevec |
• Heparin |
• Humira and Remicade |
• Hydroquinone |
• Hydroxycut |
• Januvia® and Janumet® Information |
• Kava Kava |
• Ketek |
• Lariam |
• Levaquin |
• Lupron (Leuprolide) |
• Meridia |
• Multaq® |
• Naproxen (Aleve) |
• Natrecor |
• Neurontin |
• Nexium® (Esomeprazole Magnesium) Heartburn Relief |
• NuvaRing® |
• Ocella Information |
• Osteonecrosis and Fosamax |
• Oxycontin |
• Palladone |
• Paxil |
• Permax |
• Plavix |
• PPA |
• Prevacid® |
• Prilosec® |
• Procrit |
• Propecia® (Finasteride) |
• Propoxyphene |
• Protonix® |
• Protopic |
• Prozac |
• What is Quinine? |
• Rapamune® Lawyer |
• Raptiva |
• Reglan |
• Remicade Lawsuit |
• Rezulin |
• Risperdal |
• Ritalin |
• Serevent |
• Seroquel |
• Serzone |
• Tequin |
• Thimerosal |
• Topamax® (Topiramate) |
• Viagra® |
• Wellbutrin® |
• Xenical |
• Yasmin® |
• Yaz Birth Control Lawyer |
• Zelnorm |
• Zocor® Medication Information |
• Zoloft |
• Zyprexa |